NO323966B1 - Histamin H<N>3</N> reseptor-ligander, farmasooytisk preparat inneholdende samme og anvendelse av samme for fremstilling av medikament - Google Patents

Histamin H<N>3</N> reseptor-ligander, farmasooytisk preparat inneholdende samme og anvendelse av samme for fremstilling av medikament Download PDF

Info

Publication number
NO323966B1
NO323966B1 NO20003918A NO20003918A NO323966B1 NO 323966 B1 NO323966 B1 NO 323966B1 NO 20003918 A NO20003918 A NO 20003918A NO 20003918 A NO20003918 A NO 20003918A NO 323966 B1 NO323966 B1 NO 323966B1
Authority
NO
Norway
Prior art keywords
alkyl
desired compound
nmr
pyrrolidin
prepared
Prior art date
Application number
NO20003918A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003918D0 (no
NO20003918L (no
Inventor
Ildiko Maria Buck
Sarkis Barret Kalindjian
Nigel Paul Shankley
Elaine Anne Harper
Gillian Fairfull Watt
Ian Duncan Linney
Original Assignee
Black James Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black James Foundation filed Critical Black James Foundation
Publication of NO20003918D0 publication Critical patent/NO20003918D0/no
Publication of NO20003918L publication Critical patent/NO20003918L/no
Publication of NO323966B1 publication Critical patent/NO323966B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20003918A 1998-02-19 2000-08-02 Histamin H<N>3</N> reseptor-ligander, farmasooytisk preparat inneholdende samme og anvendelse av samme for fremstilling av medikament NO323966B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803536.3A GB9803536D0 (en) 1998-02-19 1998-02-19 Histamine H,receptor ligands
PCT/GB1999/000464 WO1999042458A1 (fr) 1998-02-19 1999-02-15 Ligands de recepteurs d'histamine h¿3?

Publications (3)

Publication Number Publication Date
NO20003918D0 NO20003918D0 (no) 2000-08-02
NO20003918L NO20003918L (no) 2000-10-03
NO323966B1 true NO323966B1 (no) 2007-07-23

Family

ID=10827270

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003918A NO323966B1 (no) 1998-02-19 2000-08-02 Histamin H<N>3</N> reseptor-ligander, farmasooytisk preparat inneholdende samme og anvendelse av samme for fremstilling av medikament

Country Status (16)

Country Link
US (1) US6878736B1 (fr)
EP (1) EP1056733B1 (fr)
JP (1) JP2002504483A (fr)
CN (1) CN1178927C (fr)
AT (1) ATE257473T1 (fr)
AU (1) AU747804B2 (fr)
BR (1) BR9908074A (fr)
CA (1) CA2318836A1 (fr)
DE (1) DE69914062T2 (fr)
ES (1) ES2213353T3 (fr)
GB (1) GB9803536D0 (fr)
NO (1) NO323966B1 (fr)
NZ (1) NZ506720A (fr)
RU (1) RU2214406C2 (fr)
WO (1) WO1999042458A1 (fr)
ZA (1) ZA991356B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5240099A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Heterocyclic sulphonamide derivatives
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
AU2001244087A1 (en) * 2000-03-17 2001-09-24 Boehringer Ingelheim International G.M.B.H Condensed imidazoles as histamine h3 receptor ligands
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
DE60118754T2 (de) * 2000-08-08 2007-01-11 Ortho-Mcneil Pharmaceutical, Inc. Bicyclische verbindungen als h3 rezeptor liganden
DK1311482T3 (da) 2000-08-08 2007-05-07 Ortho Mcneil Pharm Inc Ikke-imidazolaryloxypiperidiner som H3-receptorligander
CZ2003685A3 (cs) 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical Inc. Neimidazolové aryloxypiperidiny
JP4653935B2 (ja) * 2001-03-29 2011-03-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ヒスタミンｈ３受容体のリガンドとして用いるに有用なイミダゾリル誘導体
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
EP1430027B1 (fr) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Nouveau derives d'aminoazetidine, d'aminopyrrolidine et d'aminopiperidine
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
WO2003031432A1 (fr) 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
EA200400661A1 (ru) 2001-12-10 2004-12-30 Орто-Макнейл Фармасьютикал, Инк. Фенилалкины
US20040002604A1 (en) 2001-12-10 2004-01-01 Richard Apodaca Phenylalkynes
EP1556046A1 (fr) 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine
PL215454B1 (pl) 2002-10-23 2013-12-31 Janssen Pharmaceutica Nv Pochodne piperazynylobenzamidu, ich zastosowanie oraz kompozycja farmaceutyczna je zawierajaca
ITTO20030668A1 (it) 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
WO2005110998A1 (fr) 2004-05-07 2005-11-24 Janssen Pharmaceutica N.V. Synthese a echelle de derives d'imidazole
EP1595881A1 (fr) * 2004-05-12 2005-11-16 Pfizer Limited Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2609185A1 (fr) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Procede de fabrication de derives de sulfamide
CA2622760C (fr) 2005-09-16 2012-12-04 Janssen Pharmaceutica N.V. Cyclopropylamines en tant que modulateurs du recepteur de l'histamine h3
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
EP2026790A2 (fr) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
WO2009089235A1 (fr) * 2008-01-07 2009-07-16 Janssen Pharmaceutica N.V. Préparation de dérivés de sulfamide
US20090182141A1 (en) * 2008-01-07 2009-07-16 Ahmed Abdel-Magid Process for the preparation of sulfamide derivatives
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
JP2014528953A (ja) * 2011-09-29 2014-10-30 ヤンセン ファーマシューティカ エヌ．ベー． スルファミド誘導体の調製プロセス
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
CN110551077B (zh) * 2019-09-24 2023-01-31 新乡市润宇新材料科技有限公司 一种光催化分子氧氧化制备n-叔丁基-2-苯并噻唑亚磺酰胺的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR346879A (fr) 1903-10-10 1905-02-13 Alba Thompson Kingsley Système de serrure à moraillon
CH342957A (de) 1958-06-10 1959-12-15 Ciba Geigy Verfahren zur Herstellung einer neuen Guanidinverbindung
CH345893A (de) 1958-06-10 1960-04-30 Ciba Geigy Verfahren zur Herstellung von neuen Guanidinen
NL251629A (fr) 1959-05-15
CH362079A (de) 1959-06-10 1962-05-31 Ciba Geigy Verfahren zur Herstellung neuer Guanidine
CH390925A (de) 1960-05-04 1965-04-30 Ciba Geigy Verfahren zur Herstellung neuer Diazaverbindungen
GB952194A (en) 1960-12-23 1964-03-11 Smith Kline French Lab New guanidine derivatives and processes for preparing the same
FR1352161A (fr) 1962-11-19 1964-02-14 Farmaceutici Italia Procédé pour la préparation d'un nouveau composé, la n-(2'-guanidinoéthyl)-2-méthylpipéridine
US3317545A (en) 1963-08-21 1967-05-02 Hoffmann La Roche [2-(2, 6-dimethylpiperidino)ethyl]guanidines and intermediates
GB1185080A (en) 1967-12-07 1970-03-18 Beecham Group Ltd Pyrrolidines
FR2313918A1 (fr) * 1975-06-09 1977-01-07 Choay Sa Methoxy-2 benzenesulfonamides n-substitues, procede pour les preparer et medicaments les contenant
NZ193654A (en) * 1979-05-16 1984-08-24 Wuelfing Johann A Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
IL60129A0 (en) * 1979-05-23 1980-07-31 Wuelfing J Kg Phenylsulphonamide derivatives,their preparation and pharmaceutical compositions containing them
DE3579000D1 (de) 1985-04-02 1990-09-06 Heumann Pharma Gmbh & Co Imidazolylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
US5274097A (en) * 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
DE3922232A1 (de) 1989-07-06 1991-01-17 Basf Ag Fungizide guanidine
EP0525203A4 (en) 1991-02-13 1994-07-06 Asahi Chemical Ind Substituted sulfonamide derivative or pharmaceutical composition containing the same
WO1992015567A1 (fr) * 1991-02-27 1992-09-17 Seed Capital Investment (Sci) B.V. Derives d'imidazoles possedant une activite agoniste ou antagoniste sur le recepteur de l'histamine h3
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
FR2694003A1 (fr) * 1992-07-21 1994-01-28 Beecham Laboratoires Nouveaux agents anti-arythmiques, leur procédé de préparation et compositions pharmaceutiques les contenant.
CA2244745A1 (fr) * 1996-02-09 1997-08-14 James Black Foundation Limited Ligands du recepteur de l'histamine h3
AU3128197A (en) 1996-05-30 1998-01-05 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite

Also Published As

Publication number Publication date
RU2214406C2 (ru) 2003-10-20
EP1056733B1 (fr) 2004-01-07
GB9803536D0 (en) 1998-04-15
WO1999042458A1 (fr) 1999-08-26
ZA991356B (en) 2000-08-21
AU747804B2 (en) 2002-05-23
AU2535499A (en) 1999-09-06
ATE257473T1 (de) 2004-01-15
CN1178927C (zh) 2004-12-08
EP1056733A1 (fr) 2000-12-06
NO20003918D0 (no) 2000-08-02
CA2318836A1 (fr) 1999-08-26
ES2213353T3 (es) 2004-08-16
NO20003918L (no) 2000-10-03
DE69914062T2 (de) 2004-10-14
JP2002504483A (ja) 2002-02-12
NZ506720A (en) 2002-03-28
DE69914062D1 (de) 2004-02-12
US6878736B1 (en) 2005-04-12
BR9908074A (pt) 2000-10-24
CN1296478A (zh) 2001-05-23

Similar Documents

Publication Publication Date Title
NO323966B1 (no) Histamin H&lt;N&gt;3&lt;/N&gt; reseptor-ligander, farmasooytisk preparat inneholdende samme og anvendelse av samme for fremstilling av medikament
JP3108719B2 (ja) 新規なｎ−アルキレンピペリジノ化合物及びそのエナンチオマー；これらを合成する方法及びこれらを含む医薬品組成物
DE60025243T2 (de) Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
EP0505868B1 (fr) Dérivés des acides N-acyl-alphaaminés
CA2532397A1 (fr) Sel d&#39;acide (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes crristallines anhydres
NO326519B1 (no) Derivater av N-(arylsulfonyl)beta-aminosyrer omfattende en substituert aminometylgruppe, fremgangsmate for fremstilling derav samt farmasoytiske preparater inneholdende de samme
IL96241A (en) Reliable aromatic compounds, preparation of intermediate compounds for them and pharmaceutical preparations containing them
CZ63199A3 (cs) Sloučeniny typu substituovaných cyklických aminů jako inhibitory metaloproteáz, způsob jejich přípravy a použití jako léčiv
AU2001273942A1 (en) Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
JP2009524628A (ja) スルホンアミド誘導体、これの調製法およびこれのオレキシン２受容体のアンタゴニストとしての使用
WO2001081303A1 (fr) Derives de la pyrrolidine et de la piperidine et leur utilisation pour le traitement de maladies neurodegeneratives
SK9402001A3 (en) Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US6080871A (en) Sulfonamides and sulfamides as H3 receptor antagonists
US20240058303A1 (en) Proline-based neuropeptide ff receptor modulators
WO2004092128A1 (fr) Formes cristallines anhydres de (2s, 4s)-1-{(2r)-2-amino-3-&#39;4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
EP0934292B1 (fr) Inhibiteurs de metalloprotease
EP0774460A1 (fr) Compose d&#39;acide benzo que et son utilisation comme medicament
US6495715B2 (en) Calcium channel blockers
JP2008536827A (ja) 新規化合物
CA2350429A1 (fr) Agents neurotrophiques de diamide et carbamate
EP1693367A1 (fr) Compose de piperidine et procede de production de ce dernier
NZ245411A (en) Aromatic substituted amines, amides and ureas
MXPA06006072A (en) Piperidine compound and method for producing same
MXPA01007573A (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors